Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Sign Up to like & getrecommendations! Published in 2018 at "Gastroenterology"
DOI: 10.1053/j.gastro.2018.01.004
Abstract: BACKGROUND & AIMS A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic… read more here.
Keywords: corticosteroid free; patients active; remission; based symptoms ... See more keywords
Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.
Sign Up to like & getrecommendations! Published in 2018 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izy031
Abstract: Background and Aims Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers.… read more here.
Keywords: week; biologic remission; corticosteroid free; remission ... See more keywords
PTH-134 Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the east midlands
Sign Up to like & getrecommendations! Published in 2019 at "Gut"
DOI: 10.1136/gutjnl-2019-bsgabstracts.193
Abstract: Introduction Randomised controlled trials have demonstrated efficacy of vedolizumab in Ulcerative Colitis (UC) and Crohn’s Disease (CD). Further data in the real-world setting is needed to inform future practice. Methods A multicentre retrospective observational chart… read more here.
Keywords: corticosteroid free; remission; disease; disease activity ... See more keywords